Literature DB >> 8807053

Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

More than 3,000 consecutive clinical bacterial isolates from 10 U.S. medical centers were subjected to standard broth microdilution and disk diffusion tests to determine their susceptibilities to levofloxacin, ofloxacin, D-ofloxacin, and ciprofloxacin. Levofloxacin was confirmed to be twice as active as ofloxacin and to have activity comparable to that of ciprofloxacin, with minor variations in activity against some species. The prevalence of resistant isolates was 7.1% to levofloxacin, 9.3% to ciprofloxacin, and 11.2% to ofloxacin. The susceptibilities of some species to the quinolones were less than those reported in previous studies. Pseudomonas aeruginosa isolates had the greatest variability in their susceptibilities to the three drugs between the participating centers. Two proposed zone size breakpoints for levofloxacin disk tests yielded similar low error rates. Ofloxacin and ciprofloxacin susceptibility test results correlated reasonably well with those of levofloxacin and could be used as surrogate indicators of levofloxacin susceptibility, but that resulted in some serious errors, and thus, direct testing of levofloxacin susceptibility is preferable. Replicate testing of standard quality control strains confirmed the established and proposed quality control parameters for all three quinolones tested.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807053      PMCID: PMC163386     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.

Authors:  A Barry; P Fuchs; F Tenover; S Allen; D Hardy; J Jorgensen; J McLaughlin; L Reller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

3.  Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.

Authors:  M J Bale; R N Jones; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1994-05       Impact factor: 2.803

4.  Inhibition of DNA gyrase by optically active ofloxacin.

Authors:  M Imamura; S Shibamura; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.

Authors:  F R Venezio; W Tatarowicz; C A DiVincenzo; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.

Authors:  N Klesel; K H Geweniger; P Koletzki; D Isert; M Limbert; A Markus; G Riess; H Schramm; P Iyer
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

7.  Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.

Authors:  M G Cormican; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

Authors:  L D Sutton; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

9.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.

Authors:  N Yamane; R N Jones; R Frei; D J Hoban; A C Pignatari; F Marco
Journal:  J Chemother       Date:  1994-04       Impact factor: 1.714

View more
  3 in total

1.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 3.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.